A Phase 1/2 interventional study of BMS-986242 and Nivolumab in Cancer, sponsored by Bristol-Myers Squibb. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 7 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMS-986242 administered in combination with Nivolumab
Drug: BMS-986242 · Biological: Nivolumab
BMS-986242 administered in combination with Nivolumab
Drug: BMS-986242 · Biological: Nivolumab
Specified dose on specified days
Specified dose on specified days
Also known as: BMS-936558, Anti-PD-1
Number of Participants With Adverse Events (AE)
The primary objective to establish safety to be measured by the primary endpoint of AEs
Time frame: From initiation of study treatment until 100 days after discontinuation of study treatment
Number of Participants With Serious Adverse Events (SAE)
The primary objective to establish safety to be measured by the primary endpoint of SAEs
Time frame: From the date of participant's written consent until 100 days after discontinuation of nivolumab or participation in the study
Number of Participants With Dose Limiting Toxicities (DLT)
The primary objective to establish safety to be measured by the primary endpoint of dose limiting toxicities
Time frame: Approximately 2 years
Number of Participants With AEs Leading to Discontinuation
The primary objective to establish safety to be measured by the primary endpoint of AEs leading to discontinuation
Time frame: Approximately 2 years
Number of Deaths
The primary objective to establish safety to be measured by the primary endpoint of deaths
Time frame: Approximately 2 years
Number of Participants With Laboratory Abnormalities
The primary objective to establish safety to be measured by the primary endpoint of clinical laboratory test abnormalities
Time frame: Approximately 2 years
Maximum Observed Plasma Concentration (Cmax)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Time of Maximum Observed Plasma Concentration (Tmax)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Area Under the Concentration-time Curve From Time Zero to Infinity [AUC(INF)]
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Trough Observed Plasma Concentration at the End of the Dosing Interval (Ctrough)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Apparent Elimination Half-life (T-HALF)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Apparent Total Body Clearance (CLT/F)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Apparent Volume of Distribution at Steady State (Vss/F)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Accumulation Index (AI)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0. Accumulation index, calculated based on ratio of area under the curve (AUC) and Cmax at steady state to after the first dose.
Time frame: Approximately 2 years
Percent Urinary Recovery Over 24 Hours (%UR24)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Percent Urinary Recovery Over 72 Hours (%UR72)
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
Time frame: Approximately 2 years
Incidence of Anti-drug Antibody (ADA) to Nivolumab in Combination With BMS-986242
Baseline ADA-positive participant is defined as a participant who has a ADA detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.
Time frame: Approximately 2 years
Overall Response Rate (ORR)
ORR in participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors
Time frame: Approximately 2 years
| Milestone | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Started | 5 |
| Completed | 0 |
| Not completed | 5 |
| Withdrew: Administrative reason by the sponsor | 1 |
| Withdrew: Disease progression | 2 |
| Withdrew: Study drug toxicity | 1 |
| Withdrew: Adverse event unrelated to study drug | 1 |
| Milestone | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Started | 3 |
| Completed | 0 |
| Not completed | 3 |
| Withdrew: Participant withdrew consent | 1 |
| Withdrew: Other reason | 2 |
The primary objective to establish safety to be measured by the primary endpoint of AEs
| Number of participants | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Participants With Adverse Events (AE) | NA |
The primary objective to establish safety to be measured by the primary endpoint of SAEs
| Number of participants | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Participants With Serious Adverse Events (SAE) | NA |
The primary objective to establish safety to be measured by the primary endpoint of dose limiting toxicities
| Number of participants | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Participants With Dose Limiting Toxicities (DLT) | NA |
The primary objective to establish safety to be measured by the primary endpoint of AEs leading to discontinuation
| Number of participants | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Participants With AEs Leading to Discontinuation | NA |
The primary objective to establish safety to be measured by the primary endpoint of deaths
| Number of deaths | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Deaths | NA |
The primary objective to establish safety to be measured by the primary endpoint of clinical laboratory test abnormalities
| Number of participants | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Number of Participants With Laboratory Abnormalities | NA |
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0. Accumulation index, calculated based on ratio of area under the curve (AUC) and Cmax at steady state to after the first dose.
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0
No measurements were reported for this outcome.
Baseline ADA-positive participant is defined as a participant who has a ADA detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.
No measurements were reported for this outcome.
ORR in participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors
No measurements were reported for this outcome.
Collected over Adverse Events (AEs) are monitored from initiation of study treatment (monitored from participant's written consent for Serious Adverse Events) up through 100 days post-End of Treatment (EOT); Study Start of December 2017 and Study End of August 2018 (assessed approximately 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-986242 12.5 mg + Nivolumab 480 mg | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
All treated participants; Note: study terminated following starting dose of BMS-986242 12.5 mg; dosing did not escalate.
| Age, Categorical(Participants) | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 3 |
| Age, Continuous(Years) | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Mean | 67.8 ± 7.4 |
| Sex: Female, Male(Participants) | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Female | 1 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | BMS-986242 12.5 mg + Nivolumab 480 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Aug 2018, 9 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.